Company Profile
Praxis Precision Medicines Stock Price, News & Analysis
- Ticker:
- PRAX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
370.16 USD (+15.95%)
Close
Last updated: August 6, 2026
7.19B USD
Market cap
Why the stock is moving
Following the latest company update, “Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results”, PRAX closed up 16.0% at $370.16 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Precision Neuroscience
Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies.
Ulixacaltamide
Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential tremor.
Relutrigine
Relutrigine is under Priority Review for SCN2A- and SCN8A-related developmental and epileptic encephalopathies.
Vormatrigine
Vormatrigine is an oral precision medicine being evaluated in the POWER1 study for focal-onset seizures.
Elsunersen
Elsunersen is an antisense oligonucleotide targeting the underlying biology of SCN2A-related developmental and epileptic encephalopathy.
Future catalysts
Topline POWER1 results for vormatrigine in the second quarter of 2026.
PDUFA target date for relutrigine on September 27, 2026.
Topline EMERALD results for relutrigine in broad developmental and epileptic encephalopathies in the fourth quarter of 2026.
PDUFA target date for ulixacaltamide on January 29, 2027.
Recent news
- 01
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Source: Praxis Precision Medicines
- 02
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Praxis Precision Medicines
- 03
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Source: Praxis Precision Medicines
- 04
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Source: Praxis Precision Medicines
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines (PRAX) most recently closed at 370.16 USD, a +15.95% move versus the previous session.
What is the market cap of Praxis Precision Medicines (PRAX)?
Praxis Precision Medicines currently has a market capitalization of 7.19B USD on BioPharmSignal.
What does Praxis Precision Medicines do?
Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation. Its pipeline spans movement disorders and developmental epilepsies. Ulixacaltamide Ulixacaltamide is a small-molecule T-type calcium-channel modulator under FDA review for essential...
On which exchange is PRAX stock listed?
Praxis Precision Medicines (PRAX) is associated with NASDAQ, United States, Biopharma.
What is Precision?
Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation.
Which conditions is Praxis Precision Medicines targeting with Precision?
Praxis Precision Medicines is associated with neuroscience, genetic disease based on its company overview and current catalyst commentary.
How does Praxis Precision Medicines describe recent progress with Precision?
Topline POWER1 results for vormatrigine in the second quarter of 2026. PDUFA target date for relutrigine on September 27, 2026. Topline EMERALD results for relutrigine in broad developmental and epileptic encephalopathies in the fourth quarter of 2026. PDUFA target date for ulixacaltamide on January 29, 2027.
What is Neuroscience?
Precision Neuroscience Praxis Precision Medicines develops therapies for genetically and physiologically defined disorders of neuronal excitation.